Drug updated on 5/17/2024
| Dosage Form | Injection (intravenous: 100 mg/4 mL [25 mg/mL] or 400 mg/16 mL [25 mg/mL] in a single-dose vial) |
| Drug Class | Vascular endothelial growth factor inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
- Indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
- Indicated for the treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
- Indicated for the treatment of recurrent glioblastoma in adults.
- Indicated for the treatment of metastatic renal cell carcinoma in combination with interferon-alfa.
- Indicated for the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
- Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens; in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinumsensitive recurrent disease.
Latest News
Summary
- Bevacizumab-awwb (Mvasi) is used for treating various types of cancer, including metastatic colorectal, non-squamous non-small cell lung, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent/recurrent/metastatic cervical cancer. Its effectiveness varies depending on the type of cancer, dosage administered, and combination with other chemotherapy drugs.
- The summary is based on 28 systematic reviews/meta-analyses focusing on Mvasi's efficacy and safety across different patient populations.
- In terms of treating metastatic colorectal cancer, Mvasi demonstrates stronger anti-tumor activity compared to single treatment schemes when combined with chemotherapies. However, its impact on long-term prognosis, such as the overall survival rate, isn't significantly better than controls.
- For patients with Non-Squamous Non-Small Cell Lung Cancer or Advanced Hepatocellular Carcinoma, combining Mvasi with atezolizumab has improved response rates along with manageable adverse events compared to treatments without it.
- Treating Glioblastoma or Renal Cell Carcinoma with Mvasi presents potential benefits but also requires careful consideration due to possible adverse effects.
- Platinum-sensitive recurrent ovarian cancers have shown notable improvement in progression-free survival when treated with a combination of chemotherapy and Mvasi, although this does come at an increased risk of adverse events.
- Adverse effects associated with the use of Bevacizumab include severe hypertension, arterial thromboembolism, hemorrhagic events, and gastrointestinal perforation, especially among patients being treated for Metastatic Colorectal Cancer where it was combined with certain chemotherapies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Mvasi (bevacizumab-awwb) Prescribing Information. | 2023 | Amgen, Inc., Thousand Oaks, CA |